Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

645 related articles for article (PubMed ID: 35663947)

  • 1. Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL.
    Jeyakumar N; Smith M
    Front Immunol; 2022; 13():887866. PubMed ID: 35663947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Hoffmann MS; Hunter BD; Cobb PW; Varela JC; Munoz J
    Transplant Cell Ther; 2023 Jul; 29(7):440-448. PubMed ID: 37031747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Doraiswamy A; Shah MR; Bannerji R
    Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials.
    Westin JR; Kersten MJ; Salles G; Abramson JS; Schuster SJ; Locke FL; Andreadis C
    Am J Hematol; 2021 Oct; 96(10):1295-1312. PubMed ID: 34310745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma.
    Epperla N; Kumar A; Abutalib SA; Awan FT; Chen YB; Gopal AK; Holter-Chakrabarty J; Kekre N; Lee CJ; Lekakis L; Lin Y; Mei M; Nathan S; Nastoupil L; Oluwole O; Phillips AA; Reid E; Rezvani AR; Trotman J; Zurko J; Kharfan-Dabaja MA; Sauter CS; Perales MA; Locke FL; Carpenter PA; Hamadani M
    Transplant Cell Ther; 2023 Sep; 29(9):548-555. PubMed ID: 37419325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
    Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
    Front Immunol; 2021; 12():755549. PubMed ID: 34777367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Choe JH; Abdel-Azim H; Padula WV; Abou-El-Enein M
    JAMA Netw Open; 2022 Dec; 5(12):e2245956. PubMed ID: 36520440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
    Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
    Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New and emerging therapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
    Moore DC; Peery MR; Tobon KA; Raheem F; Hwang GS; Alhennawi L; Hughes ME
    J Oncol Pharm Pract; 2022 Dec; 28(8):1848-1858. PubMed ID: 35469489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic, donor-derived, second-generation, CD19-directed CAR-T cells for the treatment of pediatric relapsed/refractory BCP-ALL.
    Del Bufalo F; Becilli M; Rosignoli C; De Angelis B; Algeri M; Hanssens L; Gunetti M; Iacovelli S; Li Pira G; Girolami E; Leone G; Lazzaro S; Bertaina V; Sinibaldi M; Di Cecca S; Iaffaldano L; Künkele A; Boccieri E; Del Baldo G; Pagliara D; Merli P; Carta R; Quintarelli C; Locatelli F
    Blood; 2023 Jul; 142(2):146-157. PubMed ID: 37172203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation.
    Cao XY; Li JJ; Lu PH; Liu KY
    Int J Hematol; 2022 Sep; 116(3):315-329. PubMed ID: 35737192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management Considerations for Patients With Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma.
    Duarte C; Kamdar M
    Am Soc Clin Oncol Educ Book; 2023 Jan; 43():e390802. PubMed ID: 37098236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma.
    Fried S; Shouval R; Walji M; Flynn JR; Yerushalmi R; Shem-Tov N; Danylesko I; Tomas AA; Fein JA; Devlin SM; Sauter CS; Shah GL; Kedmi M; Jacoby E; Shargian L; Raanani P; Yeshurun M; Perales MA; Nagler A; Avigdor A; Shimoni A
    Transplant Cell Ther; 2023 Feb; 29(2):99-107. PubMed ID: 36343892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
    Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
    Front Immunol; 2020; 11():564099. PubMed ID: 33329526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma.
    Albanyan O; Chavez J; Munoz J
    Ther Adv Hematol; 2022; 13():20406207221141511. PubMed ID: 36505886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematopoietic-cell transplantation for lymphoma in the era of genetically engineered cellular therapy: it's not quite time to scrap the old vehicle for the new car.
    Scordo M; Lin RJ; Sauter CS
    Curr Opin Hematol; 2019 Jul; 26(4):288-293. PubMed ID: 31170111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic Hematopoietic Stem Cell Transplant for Diffuse Large B-Cell Lymphoma: Evolving Role in the Era of CAR T-Cell Therapy.
    Hilal T; Mountjoy LJ
    Curr Oncol Rep; 2023 Jun; 25(6):599-607. PubMed ID: 36976461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how?
    Klyuchnikov E; Bacher U; Kroll T; Shea TC; Lazarus HM; Bredeson C; Fenske TS
    Bone Marrow Transplant; 2014 Jan; 49(1):1-7. PubMed ID: 23708703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature.
    Zhao A; Zhao M; Qian W; Liang A; Li P; Liu H
    Front Immunol; 2022; 13():1063986. PubMed ID: 36713414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging Role of Autologous CD19 CAR T-Cell Therapies in the Second-Line Setting for Large B-cell Lymphoma: A Game Changer?
    Mohty R; Moustafa MA; Aljurf M; Murthy H; Kharfan-Dabaja MA
    Hematol Oncol Stem Cell Ther; 2022 Nov; 15(3):73-80. PubMed ID: 36395495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.